In the first action taken since its initial look into the so-called pay-for-delay agreements of the pharmaceutical sector, the European Commission will reportedly fine a generic drug manufacturer in a move that suggests the regulator is ready to fight what it considers an anticompetitive, consumer-harming practice. Lundbeck, based in Denmark, as well as eight other generic drug makers will be fined by the Commission for entering into the agreements, which the Commission found to have blocked access to cheaper drugs for consumers. Since the probe was first launched into the sector in 2009, the Commission has determined that consumers could be hit with up to 20 percent markups for brand name prescription drugs. Both the US and the European Union are looking to clamp down on the anticompetitive practice. Reports say the EU will announce the fines later this month, according to Commission officials.
Featured News
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
UK Court Confirms Government Demand for Access to Apple’s Encrypted Data
Nov 19, 2026 by
CPI
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff